Description: JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. It also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. using immune cells. The company was founded in 1981 and is based in Seoul, South Korea.
Home Page: www.jw-shinyak.co.kr
2477, Nambusunhwan-ro
Seoul,
137-864
South Korea
Phone:
82 2 2109 3300
Officers
| Name | Title |
|---|---|
| Lee Gyeong Ha | Co-Chief Exec. Officer |
| Jin-Hwan Kim | Co-Chief Exec. Officer |
| Dong-Yeol Yu | Director of Management Planning Office and Inside Director |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 1.3569 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |